Madrigal Pharmaceuticals CEO Sibold sells 7,616 shares for $2.5 million.

Madrigal Pharmaceuticals, Inc. (MDGL) has recently announced that Director, President, and CEO, William John Sibold, has executed a transaction involving the sale of 6485 shares at a price of $400.03 per share on August 21, 2025. Furthermore, Sibold has also sold an additional 1131 shares at a price of $401 per share on the same date.

Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has reported significant insider trading activity involving its Director, President, and CEO, William John Sibold. On August 21, 2025, Sibold executed a transaction selling 6485 shares at a price of $400.03 per share, and an additional 1131 shares at a price of $401 per share on the same date [1].

The transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. The shares were sold in multiple transactions at prices ranging from $400.00 to $400.50 and from $401.00 to $401.01, inclusive. The weighted average prices reported for the transactions are $400.0347 and $401.0003, respectively [1].

These transactions occurred amidst recent regulatory approvals and company announcements. Madrigal Pharmaceuticals has secured conditional marketing authorization for its treatment, Rezdiffra, for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) from regulators in Europe. The company has also announced grants of equity awards to new non-executive employees as part of its 2025 Inducement Plan [2, 3].

Madrigal Pharmaceuticals is focused on delivering novel therapeutics for MASH, a liver disease with high unmet medical need. Rezdiffra, a once-daily, oral, liver-directed THR-β agonist, is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [3].

Investors and financial professionals should closely monitor the company's ongoing clinical trials and regulatory approvals to assess the potential impact on the stock price and overall business performance.

References:
[1] https://www.stocktitan.net/sec-filings/MDGL/form-4-madrigal-pharmaceuticals-inc-insider-trading-activity-10206bb7ead3.html
[2] https://www.marketwatch.com/story/madrigal-pharmaceuticals-liver-disease-treatment-gets-eu-approval-224a15e4
[3] https://www.nasdaq.com/press-release/madrigal-pharmaceuticals-announces-grants-inducement-awards-under-nasdaq-listing-2